DX-9065A hydrochloride pentahydrate | CAS#155204-81-2 | 150612-55-8

MedKoo Cat#: 530412 | Name: DX-9065A HCl hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DX-9065A is a factor Xa inhibitor potentially for the treatment of acute coronary syndromes, thrombosis and angina. DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa. DX-9065a is a competitive inhibitor of the Spectrozyme FXa (SpFXa) cleavage by both fXa and prothrombinase with similar K(i) values of approximately 10-20 nM.

Chemical Structure

DX-9065A HCl hydrate

CAS#155204-81-2 (HCl, hydrate)

Theoretical Analysis

MedKoo Cat#: 530412

Name: DX-9065A HCl hydrate

CAS#: 155204-81-2 (HCl, hydrate)

Chemical Formula: C26H39ClN4O8

Exact Mass:

Molecular Weight: 571.07

Elemental Analysis: C, 54.68; H, 6.88; Cl, 6.21; N, 9.81; O, 22.41

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

150612-55-8 (free base) 150611-74-8 (HCl) 155204-81-2 (HCl hydrate) 201933-30-4 (racemic) 155204-80-1 (R-isomer)

Synonym

DX-9065A; DX 9065A; DX9065A; DX-9065; DX 9065; DX9065; DX-9065A HCl hydrate; DX-9065A hydrochloride pentahydrate

IUPAC/Chemical Name

(S)-3-(7-carbamimidoylnaphthalen-2-yl)-2-(4-(((S)-1-(1-iminoethyl)pyrrolidin-3-yl)oxy)phenyl)propanoic acid hydrochloride pentahydrate

InChi Key

LJCBAPRMNYSDOP-LVCYMWGESA-N

InChi Code

InChI=1S/C26H28N4O3.ClH.5H2O/c1-16(27)30-11-10-23(15-30)33-22-8-6-19(7-9-22)24(26(31)32)13-17-2-3-18-4-5-20(25(28)29)14-21(18)12-17;;;;;;/h2-9,12,14,23-24,27H,10-11,13,15H2,1H3,(H3,28,29)(H,31,32);1H;5*1H2/t23-,24-;;;;;;/m0....../s1

SMILES Code

O=C(O)[C@H](C1=CC=C(O[C@@H]2CN(C(C)=N)CC2)C=C1)CC3=CC=C4C=CC(C(N)=N)=CC4=C3.[H]Cl.[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 155204-81-2 (DX-9065a hydrochloride pentahydrate) 150612-55-8 (DX-9065a free base)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 571.07 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Graff J, Picard-Willems B, Harder S. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int J Clin Pharmacol Ther. 2007 Apr;45(4):237-43. PubMed PMID: 17474542. 2: Fujii Y, Takahashi M, Morita H, Kikuchi H, Aramaki Y, Amidon GL. Characteristics of gastrointestinal absorption of DX-9065a, a new synthetic anticoagulant. Drug Metab Pharmacokinet. 2007 Feb 25;22(1):26-32. PubMed PMID: 17329908. 3: Murayama N, Nakaoka M, Sudo K. Contribution of lysosomes to concentrative uptake of DX-9065a into rat liver. J Pharm Sci. 2006 Aug;95(8):1763-70. PubMed PMID: 16795022. 4: Matsushita K, Imamura T, Tancharoen S, Tatsuyama S, Tomikawa M, Travis J, Potempa J, Torii M, Maruyama I. Selective inhibition of Porphyromonas gingivalis growth by a factor Xa inhibitor, DX-9065a. J Periodontal Res. 2006 Jun;41(3):171-6. PubMed PMID: 16677284. 5: Matsushita K, Imamura T, Tomikawa M, Tancharoen S, Tatsuyama S, Maruyama I. DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa. J Periodontal Res. 2006 Apr;41(2):148-56. PubMed PMID: 16499718. 6: Becker RC, Alexander JH, Dyke C, Huang Y, Saint-Jacques H, Hasselblad V, Harrington RA, Bovill EG; XaNADU-1B Investigators.. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. Thromb Res. 2006;117(4):439-46. PubMed PMID: 15882894. 7: Becker RC, Alexander JH, Li Y, Robertson T, Kunitada S, Spencer FA, Yang H, Harrington RA. Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor. J Thromb Thrombolysis. 2004 Dec;18(3):193-7. PubMed PMID: 15815881. 8: Becker RC, Alexander J, Li YF, Bovill E, Spencer FA, Robertson TL, Kunitada S, Dyke CK, Harrington RA. Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist. Thromb Haemost. 2004 Dec;92(6):1229-31. PubMed PMID: 15622616. 9: Becker RC, Alexander J, Dyke CK, Harrington RA. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb Haemost. 2004 Dec;92(6):1182-93. Review. PubMed PMID: 15583722. 10: Shu E, Matsuno H, Ishisaki A, Kitajima Y, Kozawa O. Lack of plasminogen activator inhibitor-1 enhances the preventive effect of DX-9065a, a selective factor Xa inhibitor, on venous thrombus and acute pulmonary embolism in mice. Pathophysiol Haemost Thromb. 2003 Jul-2004 Aug;33(4):206-13. PubMed PMID: 15583451. 11: Komoriya S, Kanaya N, Nagahara T, Yokoyama A, Inamura K, Yokoyama Y, Katakura S, Hara T. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites. Bioorg Med Chem. 2004 May 1;12(9):2099-114. PubMed PMID: 15080912. 12: Gerbutavicius R, Iqbal O, Messmore HL, Wehrmacher WH, Hoppensteadt DA, Gerbutaviciene R, Griniute R, Fareed J. Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test. Clin Appl Thromb Hemost. 2003 Oct;9(4):317-23. PubMed PMID: 14653441. 13: Kaiser B. DX-9065a Daiichi. Curr Opin Investig Drugs. 2003 Sep;4(9):1105-12. Review. PubMed PMID: 14582456. 14: Kaiser B. DX-9065a, a direct inhibitor of factor Xa. Cardiovasc Drug Rev. 2003 Summer;21(2):91-104. Review. PubMed PMID: 12847561. 15: Chino D, Fujita Y, Ishii K, Nakayama K. Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats. J Pharmacol Sci. 2003 Apr;91(4):319-29. PubMed PMID: 12719661. 16: Tobu M, Iqbal O, Ma Q, Schultz C, Jeske W, Hoppensteadt D, Lewis B, Fareed D, Fareed J. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use. Clin Appl Thromb Hemost. 2003 Jan;9(1):1-17. PubMed PMID: 12643318. 17: Rezaie AR. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost. 2003 Jan;89(1):112-21. PubMed PMID: 12540961. 18: Nagashima H. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44. PubMed PMID: 12496240. 19: Shimbo D, Osende J, Chen J, Robbins J, Shimoto Y, Kunitada S, Fuster V, Badimon JJ. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thromb Haemost. 2002 Nov;88(5):733-8. PubMed PMID: 12428086. 20: Nagashima H. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. II. Effects on fibrinolysis. J Biol Chem. 2002 Dec 27;277(52):50445-9. PubMed PMID: 12397070.